Evidence map›Paper›PMID 27258230›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2016

Sex-Related Differences in Inflammatory and Immune Activation Markers Before and After Combined Antiretroviral Therapy Initiation.

Jyoti S Mathad, Nikhil Gupte, Ashwin Balagopal, David Asmuth, James Hakim, Breno Santos, Cynthia Riviere, Mina Hosseinipour, Patcharaphan Sugandhavesa, Rosa Infante and 12 more

Open access · greenAbstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 3 pooled it
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 3 syntheses or guidelines pooled it, 70 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Review
  10. Brief Report: Sex and HIV Modify Immune Activation Biomarkers in Ugandans Post-Tuberculosis.Journal of acquired immune deficiency syndromes (1999) · 2025
    Article
  11. Observational
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 17 institutions in 9 countries.

Jyoti S Mathad*Division of Infectious Diseases, Center for Global Health, Weill Cornell Medical College, New York, NY; †Johns Hopkins Clinical Trials Unit, Byramjee Jeejeebhoy Government Medical College, Pune, India; ‡Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD; §Division of Infectious Diseases, Department of Internal Medicine, University of California Davis Medical Center, Sacramento, CA; ‖Department of Medicine, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe; ¶Division of Infectious Diseases, Hospital Nossa Senhora de Conceição, Porto Alegre, Brazil; #Les Centres GHESKIO, Port-Au-Prince, Haiti; **Department of Medicine, University of North Carolina-Lilongwe, Lilongwe, Malawi; ††Research Institute for Health Sciences, Chiang Mai, Thailand; ‡‡Impacta Peru, San Miguel, Peru; §§Durban International Clinical Research Site, Durban University of Technology, Durban, South Africa; ‖‖STD/AIDS Clinical Research Laboratory, Instituto de Pesquisa Clinica Evandro Chagas, Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil; ¶¶Department of Medicine, University of Witwatersrand, Johannesburg, South Africa; ##National AIDS Research Institute (ICMR), Pune, India; ***Malawi College of Medicine-Johns Hopkins University Research Project, Blantyre, Malawi; †††YRGCARE Medical Center, Chennai, India; ‡‡‡Investigative Medicine Branch, Laboratório Integrado de Microbiologia e Imunorregulação (LIMI), Centro de Pesquisas Gonçalo Moniz (CPqGM), Fundação Oswaldo Cruz (FIOCRUZ), Salvador, Brazil; §§§Division of Infectious Diseases, University of Colorado-Denver, Aurora, CO; ‖‖‖Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA; and ¶¶¶Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL.
Nikhil Gupte
Ashwin Balagopal
David Asmuth
James Hakim
Breno Santos
Cynthia Riviere
Mina Hosseinipour
Patcharaphan Sugandhavesa
Rosa Infante
Sandy Pillay
Sandra W Cardoso
Noluthando Mwelase
Jyoti Pawar
Sima Berendes
Nagalingeswaran Kumarasamy
Bruno B Andrade
Thomas B Campbell
Judith S Currier
Susan E Cohn
Amita Gupta
New Work Concept Sheet 319 and AIDS Clinical Trials Group A5175 (PEARLS) Study Teams
Johns Hopkins University · USFundação Oswaldo Cruz · BRAsociación Civil Impacta Salud y Educación · PEChiang Mai University · THCornell University · USDurban University of Technology · ZAGheskio Centers · HTHospital Nossa Senhora da Conceição · BRJohns Hopkins Medicine · USNational AIDS Research Institute · INNorthwestern University · USUniversity of California Davis Medical Center · USUniversity of California, Los Angeles · USUniversity of Colorado Denver · USUniversity of the Witwatersrand · ZAUniversity of Zimbabwe · ZWYR Gaitonde Centre for AIDS Research and Education · IN

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
UCLA AIDS Prevention and Treatment Clinical Trials UnitUM1AI069424 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Judith S. Currier, RAPHAEL J LANDOVITZ · 2012 to 2026
$51.8M
The Johns Hopkins Baltimore-Washington-India Clinical Trials Unit (BWI CTU)UM1AI069465 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Charles W. Flexner, Amita Gupta · 2012 to 2026
$34.1M
Wits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplicationUM1AI069463 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI REES, HELEN, SANNE, IAN MATTHIAS · 2012 to 2025
$31.8M
Thailand HIV/AIDS and Infectious Disease Clinical Trials Unit (THAI CTU)UM1AI069399 · NIAID · CHIANG MAI UNIVERSITY · PI Kiat Ruxrungtham, Khuanchai Supparatpinyo · 2012 to 2026
$25.0M
Northwestern University Clinical Trial UnitUM1AI069471 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Chad J Achenbach · 2012 to 2026
$24.6M
The Progression of Hepatitis C Among IDUs with HIVR01DA016078 · NIDA · JOHNS HOPKINS UNIVERSITY · PI BALAGOPAL, ASHWIN, THOMAS, DAVID L · 2002 to 2016
$10.9M
T32: Pathogenesis of Infectious Diseases Training ProgramT32AI007613 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI ROY M. GULICK · 1999 to 2026
$8.8M
WOMEN'S HEALTH AGENDAU01AI027668 · NIAID · JOHNS HOPKINS UNIVERSITY · PI FLEXNER, CHARLES W. · 1988 to 2006
$8.7M
NCATS NIH HHS KL2 TR000458NIAID NIH HHS P30 AI094189NIAID NIH HHS R01 AI080417NIAID NIH HHS T32 AI007613NIAID NIH HHS U01 AI027668NIAID NIH HHS U01 AI069419NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069399NIAID NIH HHS UM1 AI069424NIAID NIH HHS UM1 AI069463NIAID NIH HHS UM1 AI069465NIAID NIH HHS UM1 AI069471NIAID NIH HHS UM1 AI106701NIDA NIH HHS R01 DA016078
6 · The paper itself

Abstract

backgroundWomen progress to death at the same rate as men despite lower plasma HIV RNA (viral load). We investigated sex-specific differences in immune activation and inflammation as a potential explanation.

methodsInflammatory and immune activation markers [interferon γ, tumor necrosis factor (TNF) α, IL-6, IL-18, IFN-γ-induced protein 10, C-reactive protein (CRP), lipopolysaccharide, and sCD14] were measured at weeks 0, 24, and 48 after combination antiretroviral therapy (cART) in a random subcohort (n = 215) who achieved virologic suppression in ACTG A5175 (Prospective Evaluation of Antiretrovirals in Resource-Limited Settings). Association between sex and changes in markers post-cART was examined using random effects models. Average marker differences and 95% confidence intervals were estimated using multivariable models.

resultsAt baseline, women had lower median log10 viral load (4.93 vs 5.18 copies per milliliter, P = 0.01), CRP (2.32 vs 4.62 mg/L, P = 0.01), detectable lipopolysaccharide (39% vs 55%, P = 0.04), and sCD14 (1.9 vs 2.3 µg/mL, P = 0.06) vs men. By week 48, women had higher interferon γ (22.4 vs 14.9 pg/mL, P = 0.05), TNF-α (11.5 vs 9.5 pg/mL, P = 0.02), and CD4 (373 vs 323 cells per cubic millimeter, P = 0.02). In multivariate analysis, women had greater increases in CD4 and TNF-α but less of a decrease in CRP and sCD14 compared with men.

conclusionsWith cART-induced viral suppression, women have less reduction in key markers of inflammation and immune activation compared with men. Future studies should investigate the impact of these sex-specific differences on morbidity and mortality.

Indexed as

Sex FactorsAnti-HIV AgentsBiomarkersDrug Therapy, CombinationFemaleHIV InfectionsHumansInflammation MediatorsMaleAnti-HIV AgentsBiomarkersInflammation Mediators

Identifiers

PMID27258230
PMCPMC5023467
OpenAlexW2415756804

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.